A proof-of-concept phase 2 study of monoclonal antibody MDX-33 in adult subjects with chronic stable ITP.

被引：0
|
作者：
Terjanian, T
Sher, H
Vemuri, R
Windsor, K
Nicolay, U
Vessey, A
Deo, Y
Curnow, R
机构：
[1] Staten Island Univ Hosp, Staten Isl, NY USA
[2] Jacksonville Oncol Grp, Jacksonville, FL USA
[3] W Michigan Canc Ctr, Kalamazoo, MI USA
[4] Birmingham Hematol Oncol Assoc, Birmingham, AL USA
[5] Aventis Behring, King Of Prussia, PA USA
[6] Medarex Inc, Annandale, NJ USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1081
引用
收藏
页码：251A / 251A
页数：1
相关论文
共 50 条
  • [31] SAFETY AND EFFICACY OF EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF-CONCEPT STUDY
    Gaudet, D.
    Gipe, D. A.
    Khoury, E.
    Pordy, R.
    Sasiela, W.
    Chan, K. C.
    ATHEROSCLEROSIS, 2016, 252 : E254 - E255
  • [32] The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
    Alten, Rieke
    Gram, Hermann
    Joosten, Leo A.
    van den Berg, Wim B.
    Sieper, Joachim
    Wassenberg, Siegfrid
    Burmester, Gerd
    van Riel, Piet
    Diaz-Lorente, Maria
    Bruin, Gerardus Jm
    Woodworth, Thasia G.
    Rordorf, Christiane
    Batard, Yannik
    Wright, Andrew M.
    Jung, Thomas
    ARTHRITIS RESEARCH & THERAPY, 2008, 10 (03)
  • [33] The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
    Rieke Alten
    Hermann Gram
    Leo A Joosten
    Wim B van den Berg
    Joachim Sieper
    Siegfrid Wassenberg
    Gerd Burmester
    Piet van Riel
    Maria Diaz-Lorente
    Gerardus JM Bruin
    Thasia G Woodworth
    Christiane Rordorf
    Yannik Batard
    Andrew M Wright
    Thomas Jung
    Arthritis Research & Therapy, 10
  • [34] SAFETY AND EFFICACY OF EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF-CONCEPT STUDY
    Gaudet, Daniel
    Gipe, Daniel
    Hovingh, Kees
    Ahmad, Zahid
    Cuchel, Marina
    Shah, Prediman
    Chyu, Kuang-Yuh
    Pordy, Robert
    Sasiela, William
    Chan, Kuo-Chen
    Khoury, Etienne
    ATHEROSCLEROSIS, 2017, 263 : E9 - E9
  • [35] Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study
    Taylor, Matthew H.
    Betts, Courtney B.
    Maloney, Lauren
    Nadler, Eric
    Algazi, Alain
    Guarino, Michael J.
    Nemunaitis, John
    Jimeno, Antonio
    Patel, Priti
    Munugalavadla, Veerendra
    Tao, Lin
    Adkins, Douglas
    Goldschmidt, Jerome H., Jr.
    Cohen, Ezra E. W.
    Coussens, Lisa M.
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 903 - 914
  • [36] Natalizumab treatment of progressive multiple sclerosis reduces inflammation and tissue damage - results of a phase 2A proof-of-concept study
    Christensen, J. Romme
    Ratzer, R.
    Bornsen, L.
    Garde, E.
    Lyksborg, M.
    Siebner, H. R.
    Dyrby, T. B.
    Sorensen, P. S.
    Sellebjerg, F.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 514 - 515
  • [37] Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study
    Archer, David F.
    Stewart, Elizabeth A.
    Jain, Rita I.
    Feldman, Robert A.
    Lukes, Andrea S.
    North, Janine D.
    Soliman, Ahmed M.
    Gao, Jingjing
    Ng, Juki W.
    Chwalisz, Kristof
    FERTILITY AND STERILITY, 2017, 108 (01) : 152 - +
  • [38] The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results
    Feagan, B. G.
    Sands, B.
    Siegel, C. A.
    Dubinsky, M.
    Longman, R.
    Sabinho, J.
    Laurent, O.
    Luo, A.
    Lu, J. D.
    Nguyen, D.
    Towfic, F.
    DuVall, A.
    Woyranowski, M.
    Al Kharrat, H.
    McGovern, D. P. B.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I162 - I164
  • [39] The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results
    Feagan, Brian G.
    Sands, Bruce E.
    Siegel, Corey A.
    Dubinsky, Marla C.
    Longman, Randy
    Sabino, Joao
    Laurent, Olivier
    Luo, Allison
    Lu, J. D.
    Nguyen, Deanna D.
    Towfic, Fadi
    DuVall, Aaron
    Woynarowski, Marek
    Al Kharrat, Houssam
    McGovern, Dermot
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S875 - S876
  • [40] Somatostatin analogues as second-line treatment in adult patients with recurrent medulloblastoma: A case report and a concept for a multicentric, open-label, proof-of-concept, phase I study
    Glas, M.
    Hirschmann, B.
    Steinbrecher, A.
    Hau, P.
    Bogdahn, U.
    NEURO-ONCOLOGY, 2006, 8 (04) : 341 - 341
12345